ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Circulating Natural Killer Cells in Patients With Type 2 Diabetes and Peripheral Neuropathy Are Altered in Their Frequency and Exhibit Impaired Functions and Angiogenic Activities.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Patients with type 2 diabetes mellitus (T2DM) and critical limb-threatening ischemia (CLTI), a severe vascular complication associated with amputation and high mortality, exhibit chronic inflammation and endothelial dysfunction. We previously reported an increased frequency of natural killer (NK) cells in advanced CLTI; however, whether NK cell alterations are already present in patients with peripheral neuropathy, which often precedes diabetic foot lesions with or without distal macroangiopathy, remains unclear. We conducted an observational pilot study to assess circulating NK cell frequency by flow cytometry and inflammatory plasma cytokines profiling by ELISA in 177 subjects stratified into five groups: healthy controls (HC, n = 25); T2DM without neurovascular complications (D, n = 26); non-macrovascular neuropathic T2DM without foot lesions (N, n = 40); non-macrovascular neuropathic T2DM with lower-limb ulcers/lesions/osteomyelitis (N1, n = 42); and macrovascular revascularized neuropathic T2DM with ulcers/lesions/osteomyelitis (NV, n = 44). NK cell subset frequencies were evaluated in an independent cohort of patients with non-macrovascular neuropathic T2DM (n = 22) and healthy controls (n = 23). NKs were further characterized for degranulation capacity, secretome composition, and pro-angiogenic activity in vitro and in vivo (Hirudo verbana). NK cell frequency was significantly increased in patients with non-macrovascular neuropathic T2DM compared with controls and was accompanied by elevated plasma levels of soluble mediators associated with NK cell activation and function, including TNF-α, IL-12p70, MCP-1, and IL-4. NKs from these patients exhibited impaired degranulation and reduced angiogenic capacity in vitro and in vivo. Their secretome is characterized by decreased release of pro-angiogenic factors and increased secretion of mediators involved in monocyte/macrophage recruitment, resulting in enhanced macrophage recruitment in vivo. If confirmed in larger cohorts, higher frequency and functional impairment of circulating NKs may act as novel therapeutic targets and prognostic biomarkers in peripheral vascular complications of T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.